AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

PMGC Holdings Inc.

$4.46 -$1358.74 (-99.67%)
NASDAQ · 14 Sep 2026 13:52 UTC
Previous Close
$4.52
Day Range
$4.45$4.6
Year Range
$4.4$2671.2
Market Cap
2.03M
AVG Volume
221.64K
Trailing/Forward PE
-0/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
-2M02M4M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q22.58M
26 Q11.27M
25 Q4590.08K
25 Q3-1.46M
25 Q2-1.75M
25 Q1-1.75M
24 Q4-1.13M
24 Q31.31M
24 Q21.87M
24 Q12.18M
Net Income (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-13.49M
26 Q1-11.11M
25 Q4-7.75M
25 Q3-6.7M
25 Q2-5.61M
25 Q1-6.46M
24 Q4-6.25M
24 Q3-5.47M
24 Q2-4.75M
24 Q1-4.62M
Operating Income (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-12.3M
26 Q1-9.5M
25 Q4-7.38M
25 Q3-4.06M
25 Q2-2.49M
25 Q1-2.03M
24 Q4-1.63M
24 Q3-3.06M
24 Q2-3.22M
24 Q1-3.67M
EBITDA (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-11.97M
26 Q1-9.03M
25 Q4-7.44M
25 Q3-4.2M
25 Q2-3.48M
25 Q1-4.26M
24 Q4-3.2M
24 Q3-4.68M
24 Q2-3.79M
24 Q1-3.7M
Cash Flows (USD) · TTM
-10M-7.5M-5M-2.5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-8.99M
26 Q1-8.37M
25 Q4-6.38M
25 Q3-6.58M
25 Q2-5.43M
25 Q1-4.92M
24 Q4-5.96M
24 Q3-6.05M
24 Q2-6.13M
24 Q1-6.05M
EPS (USD) · TTM
-40000-30000-20000-10000024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-1815.3
26 Q1-2188.5
25 Q4-4557.3
25 Q3-7257.7
25 Q2-14076.1
25 Q1-22774.66
24 Q4-29771.76
24 Q3-34410.24
24 Q2-26417.28
24 Q1-17362.08
Expenses (USD) · TTM
-2M02M4M6MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q22.07M
26 Q12.16M
25 Q42.21M
25 Q31.35M
25 Q22.06M
25 Q12.95M
24 Q42.7M
24 Q35.4M
24 Q25.2M
24 Q14.45M
Shares Outstanding (USD) · TTM
-600K-400K-200K0200KBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ELAB Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-174.54K
26 Q1-15.84K
25 Q419.34K
25 Q3-9.65K
25 Q2-43.51K
25 Q117.19K
24 Q4-97.17K
24 Q3-198.71K
24 Q2-313.15K
24 Q1-467.92K
Employee Count
010203040202320242025
ELAB Employee Count by quarter
PeriodEmployee Count
202532
20242
202316
Free Cash Flow Yield
-20000%-15000%-10000%-5000%0%med -70.48%Aug 24Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26
ELAB Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Apr 26-12583.28%
Apr 26-9552.55%
Apr 26-6541.21%
Apr 26-5477.69%
Mar 26-17893.43%
Mar 26-8489.21%
Mar 26-6524.46%
Mar 26-6730.19%
Feb 26-4185.16%
Feb 26-3860.73%
Feb 26-3635.28%
Feb 26-2829.74%
Jan 26-1418.9%
Jan 26-1418.9%
Jan 26-1566.14%
Jan 26-948.64%
Jan 26-219.2%
Dec 25-200.82%
Dec 25-137.73%
Dec 25-80.85%
Dec 25-62.76%
Nov 25-58.62%
Nov 25-65.95%
Nov 25-58.73%
Nov 25-70.28%
Oct 25-64.36%
Oct 25-63.18%
Oct 25-55.39%
Oct 25-69.77%
Oct 25-71.47%
Sep 25-70.67%
Sep 25-65.57%
Sep 25-79.84%
Sep 25-84.25%
Aug 25-67.31%
Aug 25-45.98%
Aug 25-56.45%
Aug 25-120.08%
Aug 25-115.68%
Jul 25-99.01%
Jul 25-95.65%
Jul 25-102.08%
Jul 25-100.78%
Jun 25-105.49%
Jun 25-109.58%
Jun 25-108.53%
Jun 25-103.96%
May 25-107.94%
May 25-96%
May 25-91.34%
May 25-123.98%
May 25-119.95%
Apr 25-130.56%
Apr 25-113.49%
Apr 25-96.07%
Apr 25-68.94%
Mar 25-60.82%
Mar 25-194.09%
Mar 25-228.98%
Mar 25-189.91%
Feb 25-109.84%
Feb 25-82.88%
Feb 25-80.43%
Feb 25-72.73%
Jan 25-79.95%
Jan 25-44.11%
Jan 25-64.19%
Jan 25-66.38%
Jan 25-55.13%
Dec 24-56.04%
Dec 24-53.41%
Dec 24-59.7%
Dec 24-67.03%
Nov 24-66.69%
Nov 24-34.01%
Nov 24-30.94%
Nov 24-44.19%
Nov 24-28.9%
Oct 24-8.24%
Oct 24-8.97%
Oct 24-8.91%
Oct 24-7.73%
Sep 24-9.05%
Sep 24-2.98%
Sep 24-2.39%
Sep 24-2.87%
Aug 24-3.14%
Aug 24-2.72%
Aug 24-2.81%
Aug 24-2.64%
Aug 24-2.23%
Jul 24-1.98%
Jul 24-1.75%
Jul 24-1.74%
Jul 24-1.52%
Jun 24-1.51%
Jun 24-1.51%
Jun 24-1.49%
Jun 24-1.38%
May 24-1.33%
Price to Sales
-1000100200300med -0.07Aug 24Nov 24Feb 25Jun 25Sep 25Jan 26Apr 26
ELAB Price to Sales by quarter
PeriodPrice to Sales
Apr 260.09
Apr 260.11
Apr 260.17
Apr 260.2
Mar 26-0.03
Mar 26-0.05
Mar 26-0.07
Mar 26-0.07
Feb 26-0.11
Feb 26-0.12
Feb 26-0.12
Feb 26-0.16
Jan 26-0.32
Jan 26-0.32
Jan 26-0.29
Jan 26-0.47
Jan 26-2.05
Dec 25-2.24
Dec 25-3.27
Dec 25-5.57
Dec 25-7.17
Nov 25-7.68
Nov 25-6.83
Nov 25-7.67
Nov 25-4.42
Oct 25-4.82
Oct 25-4.91
Oct 25-5.61
Oct 25-4.45
Oct 25-4.34
Sep 25-4.39
Sep 25-4.73
Sep 25-3.89
Sep 25-3.69
Aug 25-4.61
Aug 25-6.75
Aug 25-5.5
Aug 25-2.35
Aug 25-2.44
Jul 25-2.85
Jul 25-2.94
Jul 25-2.76
Jul 25-2.8
Jun 25-2.67
Jun 25-2.57
Jun 25-2.6
Jun 25-2.71
May 25-2.61
May 25-2.93
May 25-3.08
May 25-4.24
May 25-4.38
Apr 25-4.03
Apr 25-4.63
Apr 25-5.47
Apr 25-7.63
Mar 25-8.65
Mar 252.37
Mar 252.01
Mar 252.42
Feb 254.19
Feb 255.56
Feb 255.72
Feb 256.33
Jan 255.76
Jan 2510.44
Jan 257.17
Jan 256.94
Jan 258.35
Dec 248.22
Dec 248.62
Dec 247.71
Dec 246.87
Nov 246.9
Nov 2413.54
Nov 2414.88
Nov 247.43
Nov 2411.35
Oct 2439.8
Oct 2436.58
Oct 2436.81
Oct 2442.43
Sep 2436.26
Sep 24110.01
Sep 24137.51
Sep 24114.41
Aug 24104.66
Aug 24120.61
Aug 24116.69
Aug 24104.82
Aug 24124.13
Jul 24140.08
Jul 24158.25
Jul 24159.68
Jul 24182.03
Jun 24183.61
Jun 24183.61
Jun 24186.27
Jun 24201.02
May 24208.93
Price to Book
010203040med 0.62Dec 24Mar 25Jul 25Oct 25Jan 26May 26Sep 26
ELAB Price to Book by quarter
PeriodPrice to Book
Sep 260.13
Sep 260.15
Aug 260.15
Aug 260.19
Aug 260.27
Aug 260.03
Jul 260.03
Jul 260.03
Jul 260.04
Jul 260.04
Jul 260.04
Jun 260.04
Jun 260.05
Jun 260.05
Jun 260.05
May 260.06
May 260.06
May 260.07
Apr 260.01
Apr 260.01
Apr 260.01
Apr 260.01
Mar 260
Mar 260.01
Mar 260.01
Mar 260.01
Feb 260.02
Feb 260.02
Feb 260.02
Feb 260.03
Jan 260.05
Jan 260.05
Jan 260.05
Jan 260.08
Jan 260.35
Dec 250.39
Dec 250.56
Dec 250.96
Dec 251.23
Nov 251.32
Nov 251.18
Nov 251.32
Nov 250.85
Oct 250.93
Oct 250.95
Oct 251.08
Oct 250.86
Oct 250.84
Sep 250.85
Sep 250.91
Sep 250.75
Sep 250.71
Aug 250.89
Aug 251.3
Aug 251.06
Aug 250.5
Aug 250.52
Jul 250.61
Jul 250.63
Jul 250.59
Jul 250.6
Jun 250.57
Jun 250.55
Jun 250.56
Jun 250.58
May 250.56
May 250.63
May 250.66
May 250.72
May 250.75
Apr 250.69
Apr 250.79
Apr 250.93
Apr 251.3
Mar 251.47
Mar 250.36
Mar 250.31
Mar 250.37
Feb 250.64
Feb 250.85
Feb 250.88
Feb 250.97
Jan 250.88
Jan 251.6
Jan 251.1
Jan 251.06
Jan 251.28
Dec 241.26
Dec 241.32
Dec 241.18
Dec 241.05
Nov 241.06
Nov 242.08
Nov 242.28
Nov 245.25
Nov 248.03
Oct 2428.16
Oct 2425.88
Oct 2426.05
Oct 2430.02
PMGC Holdings Inc.
ELAB
Stockpicker

Video analysis: ELAB

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ELAB

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

globenewswire.com · 1 Sep 2026

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

globenewswire.com · 26 Aug 2026

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Acr

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

globenewswire.com · 25 Aug 2026

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

globenewswire.com · 21 Aug 2026

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

globenewswire.com · 19 Aug 2026

PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on August 21, 2026.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially

globenewswire.com · 14 Aug 2026

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-o

PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement

globenewswire.com · 29 Jul 2026

PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement

Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

globenewswire.com · 28 Jul 2026

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

NEWPORT BEACH, Calif. , July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company executing a precision manufacturing growth strategy across the aerospace and defense supply chain, today announced that its wholly owned subsidiary, A&B Aerospace, Inc.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.